# The Managed Acquisition of Chemoresistance as an Informative Tool for Tumor Research

**Authors:** Tatyana A. Grigoreva, Daria N. Kindt, Aleksandra V. Sagaidak, Angelina A. Romanova, Vyacheslav G. Tribulovich

PMC · DOI: 10.3390/ijms262110400 · 2025-10-26

## TL;DR

This paper reviews methods for creating chemoresistant cell lines to study drug resistance in tumors and develop new treatments.

## Contribution

The paper provides a comprehensive overview of modern techniques for generating chemoresistant models and their use in cancer research.

## Key findings

- Common cytostatics and targeted drugs used to induce resistance include cisplatin, paclitaxel, and doxorubicin.
- Drug resistance activates specific cell mechanisms that can be studied through controlled cell cultivation methods.
- These models help in understanding resistance and developing new therapeutic strategies.

## Abstract

The problem of acquiring chemoresistance by tumor cells is a growing concern for researchers as the effectiveness of diagnosis and treatment of primary tumors increases. To study the mechanisms of resistance, as well as to evaluate the effectiveness of new drugs, it is necessary to use adequate cell models. The review presents modern methods for obtaining chemoresistant cell lines used by researchers in such studies. It examines the most common cytostatics and targeted drugs, such as cisplatin, oxaliplatin, paclitaxel, doxorubicin, 5-fluorouracil, gemcitabine, gefitinib, bortezomib, erlotinib, and the monoclonal antibody cetuximab. Particular attention is paid to cell mechanisms activated due to drug resistance development and to methods of cell cultivation in the presence of drugs. The presented information provides an opportunity to discuss trends in the creation of chemoresistant cell lines for further research on resistance mechanisms and the development of new therapeutic strategies.

## Linked entities

- **Chemicals:** cisplatin (PubChem CID 5460033), oxaliplatin (PubChem CID 9887053), paclitaxel (PubChem CID 36314), doxorubicin (PubChem CID 31703), 5-fluorouracil (PubChem CID 3385), gemcitabine (PubChem CID 60750), gefitinib (PubChem CID 123631), bortezomib (PubChem CID 387447), erlotinib (PubChem CID 176870)

## Full-text entities

- **Diseases:** Tumor (MESH:D009369)
- **Chemicals:** 5-fluorouracil (MESH:D005472), erlotinib (MESH:D000069347), doxorubicin (MESH:D004317), gemcitabine (MESH:D000093542), cetuximab (MESH:D000068818), bortezomib (MESH:D000069286), cisplatin (MESH:D002945), gefitinib (MESH:D000077156), paclitaxel (MESH:D017239), oxaliplatin (MESH:D000077150)

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12609814/full.md

---
Source: https://tomesphere.com/paper/PMC12609814